Understanding the Growth Hormone Axis
The growth hormone (GH) axis — also called the somatotropic axis — is one of the body's primary regulatory systems for growth, metabolism, body composition, and tissue repair. GH is secreted by somatotroph cells in the anterior pituitary gland in a pulsatile pattern governed by two opposing hypothalamic signals: stimulatory GHRH (growth hormone-releasing hormone) and inhibitory somatostatin.
A third input — the ghrelin/GHS receptor pathway — amplifies GH release independently of GHRH. This tri-input architecture makes the GH axis uniquely amenable to multi-peptide research strategies, with different compounds targeting different inputs.
The Axis Architecture
- Hypothalamus → GHRH: Stimulates GH synthesis and release from pituitary somatotrophs via the GHRH receptor (cAMP/PKA pathway)
- Hypothalamus → Somatostatin: Inhibits GH release between pulses, creating the pulsatile pattern essential for GH bioactivity
- Stomach → Ghrelin: Amplifies GH release via GHS-R1a receptors (calcium/PKC pathway) independently of GHRH
- Liver → IGF-1: The primary downstream mediator of GH's systemic effects, which feeds back to suppress further GH release
GHRH Analogs: The Direct Stimulators
CJC-1295 (No DAC)
CJC-1295 is a synthetic 29-amino-acid analog of human GHRH modified to resist degradation by dipeptidyl peptidase-IV (DPP-IV). This modification extends its half-life from minutes (native GHRH) to approximately 30 minutes, allowing more sustained receptor activation.
- Dose-dependent GH increase: Teichman et al. (2006) demonstrated dose-dependent increases in GH, IGF-1, and IGFBP-3 in healthy adults
- Pulsatility preservation: Unlike exogenous GH injection, CJC-1295 stimulates endogenous GH production while preserving the natural pulsatile release pattern (Ionescu & Bhatt, 2008)
- GHRH receptor selectivity: Minimal effects on other pituitary hormones (ACTH, TSH, prolactin), confirming clean receptor specificity (Alba et al., 2006)
Sermorelin
Sermorelin (GHRH 1-29) is the first 29 amino acids of the 44-amino-acid native GHRH molecule. It was the first GHRH analog to receive FDA approval (1997) for diagnostic evaluation of pituitary GH secretory capacity.
- Historical significance: Sermorelin established the proof-of-concept that synthetic GHRH analogs could effectively stimulate endogenous GH release
- Shorter half-life: Less DPP-IV resistant than CJC-1295, resulting in shorter duration of action — a property that can be advantageous for mimicking natural GHRH pulse timing
- Pediatric research: Extensive clinical data in growth hormone deficiency assessment (Walker et al., 1990)
Tesamorelin
Tesamorelin is a GHRH analog with a trans-3-hexenoic acid modification that improves stability and potency. It is FDA-approved (2010) for reduction of excess abdominal fat in HIV patients with lipodystrophy.
- Visceral fat reduction: Falutz et al. (2007) demonstrated significant trunk fat reduction in HIV-associated lipodystrophy, establishing metabolic effects beyond simple GH elevation
- IGF-1 increase: Consistent, dose-dependent increases in IGF-1, confirming functional activation of the GH-IGF-1 axis
- Regulatory precedent: One of few GH-axis peptides with FDA approval, providing the most rigorous clinical dataset in this class
Growth Hormone Secretagogues: The Ghrelin Pathway
Ipamorelin
Ipamorelin is a pentapeptide GH secretagogue that binds the ghrelin receptor (GHS-R1a). Its distinguishing feature is exceptional selectivity.
- GH selectivity: Raun et al. (1998) demonstrated that Ipamorelin stimulates GH release without significantly affecting ACTH, cortisol, prolactin, or aldosterone — a cleaner profile than GHRP-6 or GHRP-2
- Appetite neutrality: Unlike ghrelin and GHRP-6, Ipamorelin does not significantly increase appetite, isolating GH effects from feeding behavior
- Dose saturation: GH release follows a saturable dose-response curve, suggesting physiological self-limitation (Anderson et al., 2001)
GHRP-6
GHRP-6 (Growth Hormone Releasing Peptide-6) is a hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that was one of the first synthetic GH secretagogues developed. It activates GHS-R1a with high potency but lower selectivity than Ipamorelin.
- Potent GH release: GHRP-6 produces robust GH elevation, with peak levels occurring approximately 15-30 minutes after administration
- Appetite stimulation: Unlike Ipamorelin, GHRP-6 significantly increases appetite through ghrelin pathway activation — which can be a desired effect in wasting research or an unwanted confound in metabolic studies
- Cortisol and prolactin effects: GHRP-6 can modestly increase cortisol and prolactin, reflecting its broader receptor activation profile compared to Ipamorelin
- Historical importance: Bowers et al. (1990) used GHRP-6 in landmark studies demonstrating GHRH + GHS synergy, establishing that co-activation of both pathways produces multiplicative GH release
MK-677 (Ibutamoren)
MK-677 is technically not a peptide — it is a non-peptide GH secretagogue that activates the ghrelin receptor (GHS-R1a) with oral bioavailability. It is included here because of its functional overlap with peptide secretagogues.
- Oral activity: MK-677 is orally bioavailable, unlike peptide secretagogues, with a long half-life allowing once-daily dosing
- Sustained GH/IGF-1 elevation: Murphy et al. (1998) demonstrated sustained increases in GH pulsatility and IGF-1 levels over months of continuous administration
- Body composition effects: Research shows effects on lean body mass and nitrogen balance in various populations (Nass et al., 2008)
- Sleep quality: MK-677 has been shown to increase REM sleep duration and sleep quality, likely through increased GH-associated slow-wave sleep (Copinschi et al., 1997)
Choosing the Right GH Axis Peptide for Research
- For clean GH studies: Ipamorelin (fewest off-target effects) or CJC-1295 (GHRH-specific)
- For synergy studies: CJC-1295 + Ipamorelin (GHRH + GHS co-activation)
- For metabolic research: Tesamorelin (FDA-approved, strongest clinical dataset) or MK-677 (oral, sustained)
- For appetite-inclusive models: GHRP-6 (ghrelin pathway with appetite component)
- For diagnostic protocols: Sermorelin (established clinical use in pituitary function testing)
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.